-+ 0.00%
-+ 0.00%
-+ 0.00%

Scotiabank Maintains Sector Outperform on Vertex Pharmaceuticals, Raises Price Target to $660

Benzinga·11/03/2026 17:41:46
Listen to the news
Scotiabank analyst Louise Chen maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Outperform and raises the price target from $558 to $660.